PRAN - Prana Biotechnology Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Prana Biotechnology Limited

460 Bourke Street
Level 3
Melbourne, VIC 3000
61 3 9349 4906

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.PsychCo-Founder, Exec. Chairman, CEO & MD351.19kN/A1955
Ms. Kathryn Andrews B.Com, CPAChief Financial Officer119.32kN/A1967
Ms. Dianne M. AngusChief Operating Officer274.52kN/A1960
Dr. David A. Stamler M.D.Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board45.93kN/A1961
Prof. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of R&D Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. Its lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimer's: and that is in Phase IIa clinical trials for the treatment of Huntington's diseases. The company is also developing PBT434, which is in preclinical toxicology stage for the treatment for Parkinson's disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds. The company has a research collaboration agreement with Takeda Pharmaceuticals International, Inc. to slow or prevent neurodegeneration of the gastrointestinal system through PBT434, an investigational movement disorders compound. Prana Biotechnology Limited was founded in 1997 and is based in Melbourne, Australia.

Corporate Governance

Prana Biotechnology Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.